Israeli researchers reported in the American Journal of Hematology that teens and young adults with acute lymphoblastic leukemia who were given pediatric-inspired induction chemotherapy drugs had lower all-cause mortality and relapse rates than the group receiving traditional adult chemotherapy regimens. They also found that the pediatric-inspired chemotherapy group had greater remission and event-free survival rates compared with the other group.

Related Summaries